drug development

A unique collection of 2860 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3280 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2400 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 653 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 3550 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A collection of 17839 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 1855 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3163 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1440 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening;

A unique collection of 4607 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screen

A unique collection of 4221 natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 500 natural alkaloids can be used for high throughput and high content screening;

A unique collection of 1812 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2928 compounds (TCM monomers) sourcing from traditional Chinese Medicines, is a powerful tool for drug discovery and research in mechanism;

A unique collection of 5010 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS);

891 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A unique collection of 142 microtubule-targeted compounds can be used in HTS and HCS;

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents;

A unique collection of 569 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 23619 pure natural products with diverse structures and sources covering various plant, animal, and microbe species;

Large quantity: contains 163,000 natural product derivatives and the number is continuously updating;

A unique collection of 2270 natural products included in Chinese Pharmacopoeia (CP), a powerful tool for drug development and pharmacological study;